Navigation Links
Primary Endpoint Met in Phase 2 Trial of Daclizumab in Patients,With Relapsing Multiple Sclerosis

- Anti-IL-2 receptor antibody significantly reduced the number of new or enlarged lesions compared to placebo; data to be submitted for presentation at upcoming medical meeting -

CAMBRIDGE, Mass. and FREMONT, Calif., March 12, 2007 /PRNewswire-FirstCall/ -- Biogen Idec, Inc. and PDL BioPharma, Inc. (PDL) announced today that the ongoing CHOICE trial, a Phase 2, randomized, double-blind, placebo-controlled trial of daclizumab, met its primary endpoint in relapsing multiple sclerosis (MS) patients being treated with interferon beta. Patients receiving daclizumab 2 mg/kg subcutaneously every 2 weeks showed a significant reduction in the number of new or enlarged gadolinium-contrast-enhancing lesions (Gd-CELs) at week 24.

Daclizumab is a humanized monoclonal antibody that targets the IL-2 receptor on activated T cells. Study results will be submitted for presentation at an upcoming medical meeting later this year. Based on a joint review of the 24-week data, the companies plan to initiate a Phase 2 monotherapy trial of daclizumab, and to advance the overall clinical development program in relapsing MS.

"We are very pleased to see positive results from the first randomized trial of daclizumab in patients with relapsing MS, and we look forward to advancing the clinical development program with our partner and acknowledged leader in the MS field, Biogen Idec," said Mark A. McCamish, M.D., Ph.D., chief medical officer, PDL BioPharma. "While the week 24 data set will be presented later this year, we are planning to move forward with additional development activities, most notably the initiation of the SELECT trial, which will study daclizumab as a single agent in patients with relapsing MS."

"We congratulate PDL on conducting a successful trial of daclizumab in MS," said Al Sandrock, M.D., Ph.D., senior vice president, neurology research and development, Biogen Idec. "Daclizumab represents an exciti
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
5. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
6. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
9. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 Omnicell, Inc . (NASDAQ: ... and supply management solutions and analytics software for ... Hospital (RVH) selected Omnicell G4 solutions to ... Omnicell,s hallmark flexibility and functionality, RVH became the ...
... 26, 2011 PolyGel, the manufacturer of Orthopedic, ... long term exclusive distribution agreement with China National ... in Beijing, China, Sinopharm Foreign Trade is a ... (SINOPHARM Group). (Photo:   http://photos.prnewswire.com/prnh/20110726/NY40954 ...
Cached Medicine Technology:Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4PolyGel Signs Long Term Exclusive Agreement With China's Largest Distributor of Healthcare Products 2
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... at Jefferson have found a mechanism by which a ... makes breast cancer more aggressive. Publishing in the ... prolactin, a pituitary hormone that normally stimulates breast development ... oncogene called BCL6. The BCL6 protein has previously been ...
... Predictive, Preventive and Personalised Medicine have founded, as the ... Creating a reliable scientific platform for the optimal combination ... laboratory medicine, the EPMA Journal will highlight ... and personalised medicine. The EPMA Journal ...
... , CARROLLTON, Texas , Feb. ... (AAUCM) has begun a sponsorship of the A-Claim™ medical payment ... , A-Claim ( www.A-Claim.com ) is a proprietary medical payment ... Carrollton, Texas , that is changing the way physicians, hospitals ...
... Nixon declared a "War on Cancer," the disease still claims ... expenditure of $5 billion by the U.S. government on research ... made since Nixon,s call to action in 1971, cancer research ... which is only increasing as scientists discover new drugs and ...
... ... As Strauss Radio Strategies continues to grow and expand, it has ... signing onto the GSA Schedule - the federal government procurement system. Government ... base and the addition to the GSA schedule will greatly facilitate the ...
... ... , ... February 3, 2010 -- Governance, Risk and Compliance (GRC) leader MetricStream ... over 2008 combined with record profits. MetricStream’s growth was fueled by companies prioritizing their need ...
Cached Medicine News:Health News:Springer publishes new journal in predictive, preventive and personalized medicine 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 2Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 4Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 5Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 2Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 2Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
Shandon Paraffin Block Cabinet...
Medicine Products: